Rakovina Therapeutics, Inc. 致力於基於新型DNA損傷反應技術開發新的癌症治療方法。公司總部位於加拿大不列顛哥倫比亞省溫哥華,於2020年2月7日上市。该公司專注於利用創新的去氧核糖核酸(DNA)損傷反應技術開發新型癌症療法。其藥物研發管線包括 kt-2000AI 和 kt-3000 系列。公司致力於運用專有的 Deep Docking AI 平台,快速篩選數十億種潛在藥物候選物,針對PARP(kt-2000AI)及其他新型DDR靶點,產生可推進至人體臨床試驗或與製藥合作夥伴共同開發的候選藥物。其kt-3000系列代表了一類新型雙功能小分子候選藥物,設計上結合了對聚(ADP-核糖)聚合酶(PARP)和組蛋白去乙醯化酶(HDAC)的雙重抑制作用。這種創新方法有潛力克服治療抗性,並為癌症患者帶來臨床效益。
RKVTF stock price ended at $0.13 on 星期四, after dropping 7.14%
On the latest trading day Feb 05, 2026, the stock price of RKVTF fell by 7.14%, dropping from $0.15 to $0.13. During the session, the stock saw a volatility of 23.08%, with prices oscillating between a daily low of $0.13 and a high of $0.16. On the latest trading day, the trading volume for RKVTF rose by 6.7K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 10.3K shares were traded, with a market value of approximately $2.7M.